ReviewInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2025
Mapping Plasmodium falciparum mutations in Africa: A critical review of emerging drug resistance and implications for malaria control.
Review in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Spatio-temporal trends of the prevalence of Plasmodium falciparum antimalarial drug resistance markers across sub-Saharan Africa from 2010 to 2024: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Incidence of kelch13 and Pfmdr1 gene mutations associated with antimalarial drug resistance in Plasmodium falciparum isolates from Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Changes in molecular markers of Plasmodium falciparum drug resistance between 2017 and 2024 in Southern Benin.International journal for parasitology. Drugs and drug resistance · 2026Article
- Assessing the threat of artemisinin resistance: seasonal and ecological patterns ofFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Malaria remains a significant public health concern in Africa, with the efficacy of artemisinin-based combination therapies being threatened by the emergence of Plasmodium falciparum (Pf) kelch13 mutations. The current genetic diversity of Pf and associated contributing factors reported in Africa between 2019 and 2024 were reviewed. It was shown that validated kelch13 mutations are mainly distributed in east African regions, particularly, in Eritrea (R622I, 68%) and Uganda (R561H, 52%). Emerging Pf mutations have been documented in Rwanda (C469F, 36%), Uganda (C469F, 59% and P441L, 69%), and Tanzania (P441L, 20%). Resistance markers for partner drugs, including Pfcrt, Pfmdr1, Pfdhfr, and Pfdhps, were prevalent in eastern (30-38%) and western African regions (44-55%). The key factors contributing to the development of Pf mutations were identified as drug pressure (23-35%), misuse of antimalarial drugs (10-12.5%), and cross-border population movements (10%). This review posits a critical need to refine malaria control programs, crucially reinforcing drug regulations, enhancing community awareness on appropriate treatment practices, and integrating molecular epidemiologic surveillance systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.